INNOPEA®

INNOPEA® is a dietary supplement with palmitoylethanolamide and B vitamins that contribute to normal nervous and immune system function, normal psychological function, as well as reducing fatigue and exhaustion. Thanks to its specific patented formulation, INNOPEA® contributes to the reduction of oxidative stress in chronic painful and inflammatory conditions, stimulation of the immune system and faster body recovery.

INNOPEA® thanks to its unique mechanism of action, reduces inflammation in acute and chronic inflammation, reduces the intensity of acute and chronic pain, regulates the immune response, as well as contributes to the protection of nerve cells, optimizing cognitive functions and improving quality of life.

In which conditions is the use of the product INNOPEA® recommended?

Why INNOPEA®?

What does INNOPEA® contain?

Active ingredients
1 sachet (2g)
Levagen®+
350 mg
out of which palmitoylethanolamide
315 mg
Vitamin B1 (thiamine-hydrochloride)
0,55 mg
Vitamin B6 (pyridoxine-hydrochloride)
0,70 mg
Vitamin B12 (methylcobalamin)
1,25 µg
INNOPEA® 350 mg ≈ Standard PEA 600 mg
Palmitoylethanolamide has a dose-dependent effect during administration.
Higher dose provides for better therapeutic response5.

Method of use

Adults: Dissolve the contents of the sachet in a glass of water and drink, in the morning and evening, or dissolve the contents of the sachet directly in the mouth, without adding liquid, in the morning and evening, for the first 15 days. After that, continue administration once a day.
Presentation: 15 sachets with sweetener and raspberry flavour.

Levagen®+

Levagen®+ predstavlja patentiranu formulaciju u čijem sastavu se nalazi palmitoiletanolamid proizveden specijalnom LipiSperse® tehnologijom koja povećava apsorpciju lipofilnih aktivnih supstanci. LipiSperse® „premaz sistemom“ se oblažu molekuli PEA-e čime se smanjuju hidrofobna svojstva i omogućava se:

FARMAKOKINETIČKA STUDIJA

Dizajn studije: Paralelna, dvostruko slepa studija bioraspoloživosti, u kojoj se merila koncentracija PEA-e tokom perioda od 24 sata nakon unosa 300 mg standardne PEA-e ili 300 mg PEA-e proizvedene LipiSperse® tehnologijom (Levagen+). Studija je obuhvatila 28 zdravih ispitanika.
*Increased apsorption of Palmitoylethanolamide Using a Novel Dispersion Technology System(LipiSperse®); D. Briskey at Al. 2020.
Zaključak
LipiSperse® tehnologija značajno povećava apsorpciju PEA-e gastrointestinalnom traktu, kao i koncetraciju PEA-e u krvnoj plazmi, koja je 1,75 puta viša u poređenju sa standardnom PEA-om.
Uočen je brz početak delovanja, a pik koncentracije u krvnoj plazmi je izmeren 45 minuta nakon oralne primene.

Levagen®+

Levagen®+ is a patented formulation containing palmitoylethanolamide produced by a special LipiSperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables: Sperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables:

INNOPEA® 350 mg ≈ Standard PEA 600 mg
Palmitoylethanolamide has a dose-dependent effect during administration.
Higher dose provides for better therapeutic response5.

PHARMACOKINETIC STUDY

Design: Paralel, double blind bioavailability study measuring the concentration of PEA over the period of 24 hours after intake of 300 mg of standard PEA or 300 mg of PEA produced by LipiSperse® technology on healthy subjects (n=28).